Previous 10 | Next 10 |
Rafael Holdings (NYSEMKT: RFL ): Q3 GAAP EPS of -$0.07. Revenue of $1.38M (+26.6% Y/Y) Press Release More news on: Rafael Holdings, Inc., Earnings news and commentary, Healthcare stocks news, ,
NEWARK, N.J. , June 5, 2019 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE American: RFL), reported revenue of $1.4 million and a loss per share of $0.07 for the third quarter of its 2019 fiscal year, the three months ended April 30 , 2019. 3Q19 Highlights ...
Newark, NJ, June 04, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, will present at the Jefferies 2019 Healthcare Conference on Friday, June 7 at 11:30 a.m....
Newark, NJ, May 16, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that Sanjeev Luther, President and Chief Executive Officer, was named ...
Newark, NJ, May 13, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the appointment of Mona M. Wahba, MD, MSM, as Senior Vice President f...
This article is part of a series that provides an ongoing analysis of the changes made to Kahn Brothers' 13F stock portfolio on a quarterly basis. It is based on Kahn Brothers' regulatory 13F Form filed on 05/06/2019. Please visit our Tracking Kahn Brothers Portfolio series to get an idea ...
Givat Ram High-Tech Village, Jerusalem, March 29, 2019 (GLOBE NEWSWIRE) -- Lipomedix, a clinical-stage, oncology-focused pharmaceutical company, involved in the development of innovative, safe and effective cancer therapy based on a pegylated liposomal drug delivery platform, today announce...
Rafael Pharmaceuticals, a subsidiary Rafael Holdings (NYSEAMERICAN: RFL ) is reshaping drug options for hard-to-treat forms of cancer, such as acute myeloid leukemia (AML) and metastatic pancreatic cancer. Its lead drug candidate, called devimistat (CPI-613), works to target enzymes involved...
Rafael Holdings (NYSEMKT: RFL ): Q2 GAAP EPS of -$0.08. More news on: Rafael Holdings, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
NEWARK, N.J. , March 12, 2019 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE American: RFL), reported revenue of $1.0 million and a loss per share of $0.08 for the second quarter of its 2019 fiscal year, the three months ended January 31 , 2019. Highlights Rafael...
News, Short Squeeze, Breakout and More Instantly...
Rafael Holdings Inc. Class B Company Name:
RFL Stock Symbol:
NYSE Market:
Rafael Holdings Inc. Class B Website:
NEWARK, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today announced that its Board of Directors has authorized the repurchase of up to $5 million of the Company's Class B common stock. “We remain committed to strategically and opportunistically deployi...
NEWARK, N.J., March 14, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its second quarter fiscal 2023 financial results for the three months and six months ended January 31, 2023. “Our strong balance sheet allows us to continue to fund our pipeline assets ...
NEWARK, N.J., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its first quarter fiscal 2023 financial results for the three months ended October 31, 2022. “We are pleased to have successfully completed the sale of our real estate asset located in N...